-
Are Value-Based Contracts the Answer to Ultra-High-Priced Gene Therapies? | AMCP 2024
17 Apr 2024 21:25 GMT
… and deliver the ultra-expensive treatments. One study indicates there are … therapies in phase 3 trials alone.
But there is an … the United States for Xalkori (crizotinib), which is approved to treat … used to address the Medicare best price requirement was to …
-
CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates
27 Mar 2024 16:39 GMT
… oncology therapies and precision medicines, today reported 2023 … and challenges for CStone Pharmaceuticals. We have made … and Drug Administration ("FDA") for the treatment of … been previously treated with crizotinib and platinum-based chemotherapy …
-
Was Pfizer’s breakdown of drug-price talk for Lorviqua a strategic detour?
27 Mar 2024 05:21 GMT
… Lorviqua, a cancer medicine to treat ALK positive … Lorviqua passed the Pharmaceutical Reimbursements Evaluation Committee … treatment, chemotherapy is the only treatment option if treatment … crizotinib). Patients who have failed these second-generation drugs …
-
Treatment of advanced non-small cell lung cancer with driver mutations
27 Mar 2024 01:14 GMT
… Drugs targeting MET aberrations with different binding modes included type Ia, crizotinib … mutation helps explore new classified treatment strategies. Until recently, multiomics … immunotherapy.
Journal
Frontiers of Medicine
Method of Research
Experimental …
-
A Novel Intergenic Region (chr2: 30,316,870)-ALK Fusion in a Patient with Lung Adenocarcinoma Responding to Crizotinib Combined with Pemetrexed Treatment: A Case Report
26 Mar 2024 20:33 GMT
… Respiratory and Critical Care Medicine, Ningbo No.2 Hospital … the PROFILE 1014 clinical trial has demonstrated that ALK … benefited from the treatment of crizotinib combined with pemetrexed. … the treatment of crizotinib: a case report. Invest New Drugs. 2022 …
-
Success in Clinical Trials: Putting Patients First
25 Mar 2024 19:58 GMT
… how our trials are done for these highly efficacious medications that have … Food and Drug Administration in their approval of crizotinib — basically approved crizotinib with … randomized trial showing that cisplatin was an effective drug for the treatment of …
-
FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC
15 Mar 2024 19:00 GMT
… FDA has accepted a new drug application (NDA) for ensartinib as a treatment … Pharmaceuticals.1
The regulatory agency has set a Prescription Drug … trial, ensartinib showed superior systemic and intracranial efficacy compared with crizotinib … chief medical officer …
-
FDA Accepts Xcovery’s NDA for Ensartinib
14 Mar 2024 18:13 GMT
… crizotinib in the first-line treatment of ALK-positive NSCLC. The FDA … Selvaggi, M.D., Chief Medical Officer of Xcovery. “ … and Betta Pharmaceuticals. In the clinical trials, the drug has … special offers
from American Pharmaceutical Review – all delivered …
-
Xcovery edges closer to FDA approval for NSCLC ALK inhibitor
14 Mar 2024 17:59 GMT
… China for the treatment of ALK-positive … Pfizer’s cancer drug Xalkori (crizotinib). Patients with … trials in other settings. The Phase II paediatric MATCH trial … Pharmaceutical Technology.
In the announcement accompanying the NDA, Xcovery’s chief medical …
-
U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib
13 Mar 2024 16:17 GMT
… vs crizotinib in the first-line treatment of ALK-positive NSCLC. The FDA … Giovanni Selvaggi, M.D., Chief Medical Officer of Xcovery. “We will … Xcovery and Betta Pharmaceuticals. In the clinical trials, the drug has demonstrated robust …